173 related articles for article (PubMed ID: 24123052)
1. Expression of the cancer-testis antigen BORIS correlates with prostate cancer.
Cheema Z; Hari-Gupta Y; Kita GX; Farrar D; Seddon I; Corr J; Klenova E
Prostate; 2014 Feb; 74(2):164-76. PubMed ID: 24123052
[TBL] [Abstract][Full Text] [Related]
2. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
4. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
D'Arcy V; Pore N; Docquier F; Abdullaev ZK; Chernukhin I; Kita GX; Rai S; Smart M; Farrar D; Pack S; Lobanenkov V; Klenova E
Br J Cancer; 2008 Feb; 98(3):571-9. PubMed ID: 18195709
[TBL] [Abstract][Full Text] [Related]
5. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
6. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
7. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
9. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
10. Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.
Liu X; Choi RY; Jawad SM; Arnold JT
Prostate; 2011 May; 71(7):766-77. PubMed ID: 21031436
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
Hillebrand AC; Pizzolato LS; Neto BS; Branchini G; Brum IS
PLoS One; 2018; 13(7):e0200613. PubMed ID: 30028845
[TBL] [Abstract][Full Text] [Related]
13. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
[TBL] [Abstract][Full Text] [Related]
15. HIF1alpha isoforms in benign and malignant prostate tissue and their correlation to neuroendocrine differentiation.
Monsef N; Soller M; Panagopoulos I; Abrahamsson PA
BMC Cancer; 2010 Jul; 10():385. PubMed ID: 20663134
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines.
Dahiya R; Lee C; Haughney PC; Chui R; Ho R; Deng G
Urology; 1996 Dec; 48(6):963-70. PubMed ID: 8973690
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
